医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Shanghai Institute of Materia Medica Selects Instem’s Genetic Toxicology and ReproTox Solutions to Support Growth

2015年07月21日 PM11:00
このエントリーをはてなブックマークに追加


 

CONSHOHOCKEN, Pa.

Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that the Shanghai Institute of Materia Medica (SIMM) has committed to a further, major investment in Instem solutions to support growing demand for its services.

Established in 1932, SIMM, part of the Chinese Academy of Sciences, ranks at the top in China for its drug discovery and development activities, with more than 100 drugs having been developed since its establishment. In 2010, SIMM purchased Instem’s integrated Provantis preclinical solution suite to automate study processes at its state of the art facility in Zhangjiang High-tech Park, Shanghai.

Following a successful 5 year collaborative relationship, this latest investment by SIMM includes the purchase of the Provantis® Reproductive Toxicology module, as well as a range of solutions to support growing demand for Genetic Toxicology services.

Key Facts

  • SIMM to implement the Provantis Reproductive Toxicology module to support the management, performance, analysis and reporting of all reproductive study types
  • Provantis Reproductive Toxicology to be accessed via the SaaS delivery model from Instem’s Shanghai-based data center, offering simple, cost effective software functionality, maintenance and support
  • SIMM to deploy Comet Assay IV, a live video imaging system for fast, accurate and reproducible comet slide scoring
  • SIMM to deploy the Ames Study Manager (ASM) software, an integrated suite of software for conducting the Bacterial Reverse Mutation Test, together with a Sorcerer Colony Counter and associated implementation services
  • SIMM to upgrade to Provantis 9, the latest version of Instem’s world-leading preclinical software solution

Likun Gong, Senior Toxicology Expert, SIMM, said “Provantis is without a doubt the leading solution across the world. It has been instrumental in improving our research processes and further enhancing the quality, accuracy and speed of service to our clients. We now look forward to harnessing the power of more of Instem’s solutions across our organization.”

Mr. Neil Donaldson, VP Sales Europe & Asia, Instem, commented “SIMM is renowned as one of the leading interdisciplinary centers of excellence in China and is recognized worldwide for its outstanding achievements and distinguished research team. We are honored to further cement our relationship with them and look forward to continuing our successful partnership.”

Instem’s Provantis solution was the first western toxicology/pathology software to enter into the Chinese market, deploying its initial system in one of the largest and most advanced vivariums during 2006. As the Chinese preclinical market continues to grow, Instem is leading the market, with Instem solutions deployed at more sites within the region than any competing product.

Instem has an established full-service office in Shanghai and supports organizations through traditional on-site systems as well as through its SaaS delivery model from a secure, professionally managed data center based in Shanghai.

About SIMM

Shanghai Institute of Materia Medica (SIMM), part of the Chinese Academy of Sciences (CAS) has the longest history as a comprehensive research institution for drug discovery in China. SIMM evolved from the Peking Institute of Materia Medica, Academia Sinica, founded in 1932 by Professor Chenggu Zhao. In line with its mission of “Discovering new drugs to relieve patients suffering from various diseases”, SIMM has developed and commercialized over 100 new drugs in the past 60 years.

Since the implementation of the Knowledge Innovation Program of CAS, developing novel drugs has become a paramount research focus of SIMM in recent years. In line with frontiers in life sciences, and aiming at solving key scientific problems in drug discovery, SIMM carries out both basic and applied studies and develops new theories, methods and technologies. Research priorities are given to treat major diseases, such cancers, cardio-cerebrovascular diseases, neuropsychiatric diseases, metabolic diseases, autoimmune diseases, and infectious diseases. SIMM also pays attention to the development of modern traditional Chinese Medicine (TCM).

For further information about SIMM please visit http://english.simm.cas.cn/au/bi/

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making, leading to safer, more effective products.

Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 400 clients through offices in the United States, United Kingdom, China, India and a full service distributor based in Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com

Meeting clients at the intersection of investment & return™.

http://www.linkedin.com/company/instem/

https://www.facebook.com/Instem.software

https://twitter.com/Instemsoftware

View source version on businesswire.com: http://www.businesswire.com/news/home/20150721005017/en/

CONTACT

Press Contacts:
Instem
Julie Jones (UK HQ)
+44
(0) 1785 825600
julie.jones@instem.com
or
Gary
Mitchell (US HQ)
+1 610-941-0990
Gary.mitchell@instem.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent